C4X Discovery signs research collaboration with UK subsidiary of Takeda

British company C4X Discovery has signed a research collaboration agreement with Takeda Cambridge, a UK subsidiary of Takeda Pharmaceutical (TYO: 4502), Japan’s largest pharma company.

C4X Discovery’s proprietary nuclear magnetic resonance-based technology will be applied across a number of Takeda Cambridge’s therapeutic projects. It claims to have the only technology in the world with the capacity to generate accurate, experimentally-derived 3d structures of drug molecules within days, and can be used with widely-implemented technologies for structure-based design such as x-ray.

Piers Morgan, chief executive of C4X Discovery, said: “We are delighted to partner with Takeda Cambridge, a leading pharma company with world class target identification and validation capabilities. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD’s technology.”

Andy Ayscough, senior director of chemistry at Takeda Cambridge, said: "We are pleased to partner with C4XD and are excited about the potential of this collaboration. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."